Medical cannabis company Impression Healthcare Limited has been approved for a Phase 2a Clinical Trial in Australia investigating the effectiveness of CBD-infused mouthwash and toothpaste products in the fight against gum disease. Specifically, the trial will investigate the products’ safety and effectiveness against Gingivitis and Periodontitis, which are two highly prevalent problems around the world whose treatment have so far been dominated by major pharmaceutical companies.
The trial is the result of concerted efforts by Impression and AXIM Biotechnologies Inc., a U.S.-based manufacturer of pharmaceutical-grade medical cannabis products.
AXIM, a US-based innovator in cannabinoid medicines, will supply the unique mouthwash and toothpaste products for the trial and has agreed to provide commercially available products if the trial proves successful. Impression, which is listed on the Australian Stock Exchange (ticker code ‘IHL’) with a market capitalization of about $20 million, has first right of refusal over all current and future such products by AXIM until June 2022.
“Formal registration of the gingivitis and periodontitis trial represents significant progress in IHL’s medicinal cannabis activities and is the culmination of many months of work by our team and research partners,” said Joel Latham, Impression’s CEO, in a statement. “We are excited to have assembled highly qualified researchers for a world first trial for the use of CBD in treatment of Gingivitis and Gum Disease, which are major problems representing a major market.”
Recent research from Impression’s Australian peer Botanix Pharmaceuticals indicates that CBD could have potent antibiotic properties. Lab tests from that study showed the cannabinoid was killing bacteria, including bacteria highly resistant to existing antibiotics.
Impression believes that, should the anti-inflammatory and antibiotic nature of CBD prove helpful in halting the progress of gum disease, the products will have a strong case for meeting the criteria of Category B under Australia’s Special Access Scheme, administered by the federal Therapeutic Goods Administration (TGA). This means that patients — with the approval of their doctor or dentist — would then be able to access the CBD-infused mouthwash and toothpaste products.
“We are confident that the quality of the trial will supply the requisite peer-reviewed data for unique product sales under the SAS and will further develop commercialisation opportunities for our products in this field,” said Mr. Latham.
Impression’s gum disease trial is the first of four separate clinical trials investigating unique cannabinoid products. The other three trials will cover concussion remediation, Sleep Apnea, and TMJ disorders.
Impression’s concussion trial aims to investigate neurological damage after traumatic brain injury as a result of playing Australian-centric sports; namely, the AFL (Australian Rules Football) and the NRL (National Rugby League). Similar product lines are being developed by Canadian companies Aurora Cannabis and Canopy Growth for the UFC and NHL Alumni Association, respectively.